Khalil Magdy M, Tremoleda Jordi L, Bayomy Tamer B, Gsell Willy
Biological Imaging Centre, MRC Clinical Sciences Centre, Imperial College School of Medicine, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK.
Int J Mol Imaging. 2011;2011:796025. doi: 10.1155/2011/796025. Epub 2011 Apr 5.
Molecular imaging has witnessed a tremendous change over the last decade. Growing interest and emphasis are placed on this specialized technology represented by developing new scanners, pharmaceutical drugs, diagnostic agents, new therapeutic regimens, and ultimately, significant improvement of patient health care. Single photon emission computed tomography (SPECT) and positron emission tomography (PET) have their signature on paving the way to molecular diagnostics and personalized medicine. The former will be the topic of the current paper where the authors address the current position of the molecular SPECT imaging among other imaging techniques, describing strengths and weaknesses, differences between SPECT and PET, and focusing on different SPECT designs and detection systems. Radiopharmaceutical compounds of clinical as well-preclinical interest have also been reviewed. Moreover, the last section covers several application, of μSPECT imaging in many areas of disease detection and diagnosis.
在过去十年中，分子成像发生了巨大的变化。人们对这项专门技术的兴趣与日俱增，并给予了更多关注，其代表包括新型扫描仪、药物、诊断剂、新的治疗方案，最终还有患者医疗保健的显著改善。单光子发射计算机断层扫描（SPECT）和正电子发射断层扫描（PET）在为分子诊断和个性化医疗铺平道路方面留下了印记。前者将是本文的主题，作者将阐述分子SPECT成像在其他成像技术中的当前地位，描述其优缺点、SPECT与PET之间的差异，并重点介绍不同的SPECT设计和检测系统。还对具有临床及临床前意义的放射性药物化合物进行了综述。此外，最后一部分涵盖了μSPECT成像在疾病检测和诊断的许多领域中的几种应用。
